Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...
BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced that the Biologics License Application (BLA) for the treatme...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including C...
Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...
Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system Aminex Therapeutics, Inc., a...
BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, announced the successful acquisition of Bi...
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...
In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...
Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...
As mRNA technologies move rapidly beyond COVID-19 into vaccines and therapies for cancer, rare diseases, and personalized medicine, scientific complexity i...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced a collaboration with the Stanford Center for Definitive and C...
The Seattle facility of AGC Biologics, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from Agência Nacional d...
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro...
© 2026 Biopharma Boardroom. All Rights Reserved.
